AATec Medical enriches its Scientific Council with the arrival of Professor Claus Franz Vogelmeier

AATec Medical GmbH, a biotechnology company specializing in the development of technologies based on recombinant alpha-1 antitrypsin (AAT), announced the incorporation of Professor Dr. Claus Franz Vogelmeier to its Scientific Board. A leading expert in pulmonology, Professor Vogelmeier brings significant clinical experience in the field of inflammatory lung diseases such as bronchiectasis, COPD, asthma and ARDS.

AATec CEO Dr. Rüdiger Jankowsky expressed his satisfaction with this appointment, emphasizing the importance of Vogelmeier's expertise for the advancement of inhaled AAT therapies. For his part, Professor Vogelmeier said he was enthusiastic about contributing to the development of treatments for inflammatory lung diseases, highlighting the importance of AAT in these therapeutic advances.

In addition to his role at the University of Philipps, Vogelmeier held prestigious positions such as president of the German Society of Respirology and contributed significantly to the scientific community in the field of pulmonology. His arrival strengthens the already distinguished composition of the AATec Scientific Council, promising significant advances in the therapeutic exploitation of AAT.